Mizuho Securities Maintains Surgery Partners(SGRY.US) With Buy Rating, Announces Target Price $28
BofA Securities Initiates Surgery Partners(SGRY.US) With Buy Rating, Announces Target Price $30
Surgery Partners Analyst Ratings
JPMorgan Adjusts Surgery Partners Price Target to $28 From $38, Maintains Neutral Rating
Surgery Partners Is Maintained at Outperform by RBC Capital
RBC Capital Maintains Surgery Partners(SGRY.US) With Buy Rating, Cuts Target Price to $35
Macquarie Maintains Surgery Partners(SGRY.US) With Buy Rating
TD Cowen Maintains Surgery Partners(SGRY.US) With Buy Rating, Maintains Target Price $32
Jefferies Maintains Surgery Partners(SGRY.US) With Buy Rating, Maintains Target Price $40
A Quick Look at Today's Ratings for Surgery Partners(SGRY.US), With a Forecast Between $31 to $50
Surgery Partners Analyst Ratings
Macquarie Adjusts Surgery Partners Price Target to $34 From $35, Maintains Outperform Rating
Mizuho Securities Maintains Surgery Partners(SGRY.US) With Buy Rating
Strong Q3 Performance and Strategic Growth Bolster 'Buy' Rating for Surgery Partners
Surgery Partners Price Target Maintained With a $35.00/Share by Macquarie
Macquarie Maintains Surgery Partners(SGRY.US) With Buy Rating
UBS Initiates Surgery Partners(SGRY.US) With Buy Rating, Announces Target Price $38
Surgery Partners Analyst Ratings
Surgery Partners Analyst Ratings
Surgery Partners Price Target Maintained With a $50.00/Share by Benchmark